Israeli Prime Minister Naftali Bennett has said that a new study has found that the fourth COVID-19 vaccine dose boosts antibodies five-fold.

"A week into the fourth dose we know to a higher degree of certainty that the fourth dose is safe," Bennett said at Sheba Medical Center, which is giving second booster shots in a trial among its staff amid a nationwide surge in Omicron variant infections.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/omicron-surge-could-see-israel-reach-herd-immunity-says-israeli-top-health-advisor-442233/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"A week after the administration of the fourth dose, we see a fivefold increase in the number of antibodies in the vaccinated person," Bennett added.&nbsp;

"This most likely means a significant increase in the protection against infection and against severe hospitalisation and symptoms," he said, noting the facility was due to publish its findings soon.

<a href="https://www.wionews.com/world/after-delmicron-its-flurona-israel-reports-first-double-infection-of-covid-and-flu-441504">Also read |&nbsp;After ‘Delmicron’, it's ‘flurona’: Israel reports first double infection of Covid and flu</a>

Israel has played a leading role in studying the effects of COVID-19 vaccines, as the fastest country to roll out two-dose inoculations to a wide population a year ago and one of the first to give third shots as boosters.&nbsp;

It is now administering fourth doses of the Pfizer/BioNTech vaccine to people over 60, health workers and immunocompromised patients.

<a href="https://www.wionews.com/world/israel-announces-fourth-booster-dose-for-over-60s-and-medics-as-omicron-rages-438890">Also read |&nbsp;Israel announces fourth booster dose for over 60s and medics as Omicron rages</a>

The moves come around one year after it began a massive vaccination drive on the back of a data-sharing accord with US pharmaceutical firm Pfizer.

The country's health ministry on Tuesday reported over 10,000 new coronavirus cases for the previous day, compared to a daily average of less than 4,000 the previous week.

More than four million people from Israel's population of 9.4 million have received three shots of the coronavirus vaccine.

(With inputs from agencies)

Israeli Prime Minister Naftali Bennett has said that a new study has found that the fourth COVID-19 vaccine dose boosts antibodies five-fold. "A week into the fourth dose we know to a higher degree of certainty that the fourth dose is safe," Bennett said at Sheba Medical Center, which is giving second booster shots in a trial among its staff amid a nationwide surge in Omicron variant infections.

Israeli Prime Minister Naftali Bennett has said that a new study has found that the fourth COVID-19 vaccine dose boosts antibodies five-fold. "A week into the fourth dose we know to a higher degree of certainty that the fourth dose is safe," Bennett said at Sheba Medical Center, which is giving second booster shots in a trial among its staff amid a nationwide surge in Omicron variant infections. "A week after the administration of the fourth dose, we see a fivefold increase in the number of antibodies in the vaccinated person," Bennett added. "This most likely means a significant increase in the protection against infection and against severe hospitalisation and symptoms," he said, noting the facility was due to publish its findings soon. Also read | After ‘Delmicron’, it's ‘flurona’: Israel reports first double infection of Covid and flu Israel has played a leading role in studying the effects of COVID-19 vaccines, as the fastest country to roll out two-dose inoculations to a wide population a year ago and one of the first to give third shots as boosters. It is now administering fourth doses of the Pfizer/BioNTech vaccine to people over 60, health workers and immunocompromised patients. Also read | Israel announces fourth booster dose for over 60s and medics as Omicron rages The moves come around one year after it began a massive vaccination drive on the back of a data-sharing accord with US pharmaceutical firm Pfizer. The country's health ministry on Tuesday reported over 10,000 new coronavirus cases for the previous day, compared to a daily average of less than 4,000 the previous week. More than four million people from Israel's population of 9.4 million have received three shots of the coronavirus vaccine. (With inputs from agencies)

Naftali Bennett says Israeli study finds fourth COVID-19 vaccine dose boosts antibodies five-fold

A baby born last week on the Spanish island of Ibiza has become the first newborn in Spain with coronavirus antibodies.

The boy's mother received the Covid-19 vaccine in the third trimester of her pregnancy, according to local media reports.

A sample from the baby's umbilical cord analysed at the Hospital Son Espases in Mallorca confirmed that he had developed antibodies against Covid-19, Spanish media reported.

Manuel Grandal Martin, deputy director of the Madrid Hospital Directorate, said on Friday that the protection that the baby has is equal to that of someone who has been vaccinated, the Xinhua news agency reported.

The case of the infant, named Bruno, is part of a study on the impact of Covid-19 on pregnant women. The study monitors 88 pregnant women who have caught Covid-19 during pregnancy, including those who are asymptomatic.

Other specialists believe this result opens the doors to the possibility of vaccinating pregnant women to immunise both themselves and their babies, who receive the antibodies through placenta.

(with inputs)

A baby born last week on the Spanish island of Ibiza has become the first newborn in Spain with coronavirus antibodies. The boy's mother received the Covid-19 vaccine in the third trimester of her pregnancy, according to local media reports.

A baby born last week on the Spanish island of Ibiza has become the first newborn in Spain with coronavirus antibodies. The boy's mother received the Covid-19 vaccine in the third trimester of her pregnancy, according to local media reports. A sample from the baby's umbilical cord analysed at the Hospital Son Espases in Mallorca confirmed that he had developed antibodies against Covid-19, Spanish media reported. Manuel Grandal Martin, deputy director of the Madrid Hospital Directorate, said on Friday that the protection that the baby has is equal to that of someone who has been vaccinated, the Xinhua news agency reported. The case of the infant, named Bruno, is part of a study on the impact of Covid-19 on pregnant women. The study monitors 88 pregnant women who have caught Covid-19 during pregnancy, including those who are asymptomatic. Other specialists believe this result opens the doors to the possibility of vaccinating pregnant women to immunise both themselves and their babies, who receive the antibodies through placenta. (with inputs)

First baby born in Spain with coronavirus antibodies, reports say

The US Food and Drug Administration on Monday granted emergency approval to a synthetic antibody treatment against Covid-19 developed by Eli Lilly, after the drug was shown to reduce the risk of hospitalization and emergency room visits.

Bamlanivimab at a dose of 700 milligrams was authorized for the treatment of mild-to-moderate Covid-19 in adults and children aged 12 years and older who are at high risk for progressing to the severe form of the disease.

It is the first drug to be approved that was designed specifically against the new coronavirus.

"As illustrated by today's action, the FDA remains committed to expediting the development and availability of potential COVID-19 treatments," said the agency's chief Stephen Hahn.

The approval was based on a mid-stage clinical trial for outpatients with mild to moderate Covid-19, where the intravenous treatment was shown to reduce viral loads and rates of symptoms and hospitalization.&nbsp;

The FDA said in its statement that the most important evidence that bamlanivimab may be effective came from data that showed that among patients at high risk of severe disease, hospitalizations and emergency room visits occurred in 3 percent of bamlanivimab-treated patients compared to 10 percent who were on the placebo.

The frequency and types of side effects were similar between bamlanivimab and placebo, with the majority being mild to moderate in severity.&nbsp;

The most common were diarrhea, dizziness, headache, itchiness and vomiting.

The trial is ongoing and aims to enroll more than 800 patients across various dosage groups.

An important caveat is that bamlanivimab has not been authorized for patients who are hospitalized -- since no benefit has been shown for patients who are already in this late stage of the disease, when the body's immune defenses go into overdrive and damage organs.

The FDA wrote that administering the drug too late could be associated with worse outcomes, and a trial exploring bamlanivimab in hospitalized patients was suspended last month over a safety incident.

Bamlanivimab is what's known as a monoclonal antibody, a relatively new class of drugs that are best known for treating certain types of cancer and autoimmune disease.

Human immune systems produce antibodies, which are infection-fighting proteins, and vaccines teach our bodies to be prepared to make the right ones for particular pathogens.

Bamlanivimab was based on an effective antibody Lilly found in a recovered patient.

The host immune cells that produce the antibodies can be cultured in a lab to produce the desired proteins en masse.

It works by binding to a surface protein of the coronavirus to stop it from invading human cells.

The US Food and Drug Administration on Monday granted emergency approval to a synthetic antibody treatment against Covid-19 developed by Eli Lilly, after the drug was shown to reduce the risk of hospitalization and emergency room visits.

The US Food and Drug Administration on Monday granted emergency approval to a synthetic antibody treatment against Covid-19 developed by Eli Lilly, after the drug was shown to reduce the risk of hospitalization and emergency room visits. Bamlanivimab at a dose of 700 milligrams was authorized for the treatment of mild-to-moderate Covid-19 in adults and children aged 12 years and older who are at high risk for progressing to the severe form of the disease. It is the first drug to be approved that was designed specifically against the new coronavirus. "As illustrated by today's action, the FDA remains committed to expediting the development and availability of potential COVID-19 treatments," said the agency's chief Stephen Hahn. The approval was based on a mid-stage clinical trial for outpatients with mild to moderate Covid-19, where the intravenous treatment was shown to reduce viral loads and rates of symptoms and hospitalization. The FDA said in its statement that the most important evidence that bamlanivimab may be effective came from data that showed that among patients at high risk of severe disease, hospitalizations and emergency room visits occurred in 3 percent of bamlanivimab-treated patients compared to 10 percent who were on the placebo. The frequency and types of side effects were similar between bamlanivimab and placebo, with the majority being mild to moderate in severity. The most common were diarrhea, dizziness, headache, itchiness and vomiting. The trial is ongoing and aims to enroll more than 800 patients across various dosage groups. An important caveat is that bamlanivimab has not been authorized for patients who are hospitalized -- since no benefit has been shown for patients who are already in this late stage of the disease, when the body's immune defenses go into overdrive and damage organs. The FDA wrote that administering the drug too late could be associated with worse outcomes, and a trial exploring bamlanivimab in hospitalized patients was suspended last month over a safety incident. Bamlanivimab is what's known as a monoclonal antibody, a relatively new class of drugs that are best known for treating certain types of cancer and autoimmune disease. Human immune systems produce antibodies, which are infection-fighting proteins, and vaccines teach our bodies to be prepared to make the right ones for particular pathogens. Bamlanivimab was based on an effective antibody Lilly found in a recovered patient. The host immune cells that produce the antibodies can be cultured in a lab to produce the desired proteins en masse. It works by binding to a surface protein of the coronavirus to stop it from invading human cells.

US grants emergency approval to 'Bamlanivimab' Covid-19 antibodies

A new study published on Thursday has found that children infected with novel coronavirus have generated weaker antibodies and fewer in type as compared to adults.&nbsp;

Other studies have revealed that an overly strong immune system may be responsible for people who become severely ill or die from the deadly virus. It can also be the reason why children are less likely to transmit the virus to others.

Also read | <a href="https://www.wionews.com/world/new-study-explains-long-covid-or-persistence-of-coronavirus-symptoms-340789">New study explains 'long COVID', or persistence of coronavirus symptoms</a>

A weaker immune response in children may suggest why they eliminate the virus before it has had a chance to cause trouble, and may help explain why children are mostly able to keep away the severe symptoms of Covid-19.&nbsp;

Also read | <a href="https://www.wionews.com/science/nasal-spray-prevents-covid-infection-in-ferrets-study-finds-340981">Nasal spray prevents COVID infection in ferrets, study finds</a>

"They may be infectious for a shorter time," said Donna Farber, an immunologist at Columbia University in New York who led the study, as quoted by The New York Times.&nbsp;

Other experts also said weaker and fewer antibodies do not mean that children face more risks of re-infections.&nbsp;

"You don't really need a huge, overly robust immune response to maintain protections over some period of time," said Deepta Bhattacharya, an immunologist at the University of Arizona in Tucson.&nbsp;

"I don’t know that I would be especially worried that kids have a little bit lower antibody response."

The study, which was published in journal Nature Immunology looked at antibody levels in children at a particular point in time and was too small to suggest how the levels may change with age.&nbsp;

But it could put forward questions for certain antibody tests that may be absent from children who have been infected with Covid-19.&nbsp;

 
&nbsp;

A new study published on Thursday has found that children infected with novel coronavirus have generated weaker antibodies and fewer in type as compared to adults.

A new study published on Thursday has found that children infected with novel coronavirus have generated weaker antibodies and fewer in type as compared to adults. Other studies have revealed that an overly strong immune system may be responsible for people who become severely ill or die from the deadly virus. It can also be the reason why children are less likely to transmit the virus to others. Also read | New study explains 'long COVID', or persistence of coronavirus symptoms A weaker immune response in children may suggest why they eliminate the virus before it has had a chance to cause trouble, and may help explain why children are mostly able to keep away the severe symptoms of Covid-19. Also read | Nasal spray prevents COVID infection in ferrets, study finds "They may be infectious for a shorter time," said Donna Farber, an immunologist at Columbia University in New York who led the study, as quoted by The New York Times. Other experts also said weaker and fewer antibodies do not mean that children face more risks of re-infections. "You don't really need a huge, overly robust immune response to maintain protections over some period of time," said Deepta Bhattacharya, an immunologist at the University of Arizona in Tucson. "I don’t know that I would be especially worried that kids have a little bit lower antibody response." The study, which was published in journal Nature Immunology looked at antibody levels in children at a particular point in time and was too small to suggest how the levels may change with age. But it could put forward questions for certain antibody tests that may be absent from children who have been infected with Covid-19.

Children generate weaker Covid-19 antibodies: Study

Researchers in Boston have detected long-lived antibodies in the saliva and the blood of coronavirus patients&nbsp;at least three months after symptom onset.

The study, published in the journal Science, points to the IgG class of antibodies as the longest-lasting antibodies detectable in the patients during this time frame and may serve as promising targets to detect and evaluate immune responses against the SARS-CoV-2 virus.

According to the researchers, including those from the Harvard Medical School in the US, these antibodies could be detected at similar levels in both blood and saliva, suggesting that saliva could be used as an alternative biofluid for antibody testing.

In the research, Anita Iyer and her team measured antibody responses in the blood of 343 patients with COVID-19 for up to 122 days after symptom onset, and compared these responses to those of 1,548 control individuals sampled before the pandemic.

The scientists focused only on antibodies specific to the receptor binding domain of the SARS-CoV-2 spike protein which it uses to enter host cells.

They estimated sensitivities of the antibody types IgG, IgA, and IgM at 95 per cent, 90 per cent and 81 per cent, respectively, for detecting infected individuals between 15 to 28 weeks after symptom onset.

Among these antibodies, the study noted that spike protein-specific IgM and IgA were short-lived, dropping beneath detection levels at around 49 and 71 days, respectively, after the appearance of symptoms.

However, it noted that the spike protein-targeted IgG responses decayed slowly over a period of 90 days, with only three individuals losing them within this timeframe.

According to the researchers, the levels of spike protein-specific IgG strongly correlated with levels of neutralising antibodies in the patients.

They also did not observe cross-reactivity of any SARS-CoV-2-targeting antibodies with other "common cold" coronaviruses.

Another study published in the journal Science also found that while IgA and IgM antibodies targeting the spike protein's receptor binding domain rapidly decayed, the IgG type remained relatively stable for up to 105 days after symptom onset in 402 patients with COVID-19.

In this study, researchers including Baweleta Isho from the University of Toronto in Canada, detected spike protein-specific antibodies in the saliva, as well as the blood, of these patients.

They charted the patients' antibody responses from three to 115 days after symptom onset, and compared their profiles with 339 pre-pandemic controls.

The scientists found that patients with COVID-19 showed peak IgG levels at 16 to 30 days after the appearance of symptoms.

According to the researchers, the levels of all spike protein-specific IgG, IgM, and IgA antibodies in the blood positively correlated with levels observed in matched saliva samples.

"Given that the virus can also be measured in saliva by PCR, using saliva as a biofluid for both virus and antibody measurements may have some diagnostic value," they wrote in the study.

&nbsp;

Researchers in Boston have detected long-lived antibodies in the saliva and the blood of coronavirus patients at least three months after symptom onset. The study, published in the journal Science, points to the IgG class of antibodies as the longest-lasting antibodies detectable in the patients during this time frame and may serve as promising targets to detect and evaluate immune responses against the SARS-CoV-2 virus.

Researchers in Boston have detected long-lived antibodies in the saliva and the blood of coronavirus patients at least three months after symptom onset. The study, published in the journal Science, points to the IgG class of antibodies as the longest-lasting antibodies detectable in the patients during this time frame and may serve as promising targets to detect and evaluate immune responses against the SARS-CoV-2 virus. According to the researchers, including those from the Harvard Medical School in the US, these antibodies could be detected at similar levels in both blood and saliva, suggesting that saliva could be used as an alternative biofluid for antibody testing. In the research, Anita Iyer and her team measured antibody responses in the blood of 343 patients with COVID-19 for up to 122 days after symptom onset, and compared these responses to those of 1,548 control individuals sampled before the pandemic. The scientists focused only on antibodies specific to the receptor binding domain of the SARS-CoV-2 spike protein which it uses to enter host cells. They estimated sensitivities of the antibody types IgG, IgA, and IgM at 95 per cent, 90 per cent and 81 per cent, respectively, for detecting infected individuals between 15 to 28 weeks after symptom onset. Among these antibodies, the study noted that spike protein-specific IgM and IgA were short-lived, dropping beneath detection levels at around 49 and 71 days, respectively, after the appearance of symptoms. However, it noted that the spike protein-targeted IgG responses decayed slowly over a period of 90 days, with only three individuals losing them within this timeframe. According to the researchers, the levels of spike protein-specific IgG strongly correlated with levels of neutralising antibodies in the patients. They also did not observe cross-reactivity of any SARS-CoV-2-targeting antibodies with other "common cold" coronaviruses. Another study published in the journal Science also found that while IgA and IgM antibodies targeting the spike protein's receptor binding domain rapidly decayed, the IgG type remained relatively stable for up to 105 days after symptom onset in 402 patients with COVID-19. In this study, researchers including Baweleta Isho from the University of Toronto in Canada, detected spike protein-specific antibodies in the saliva, as well as the blood, of these patients. They charted the patients' antibody responses from three to 115 days after symptom onset, and compared their profiles with 339 pre-pandemic controls. The scientists found that patients with COVID-19 showed peak IgG levels at 16 to 30 days after the appearance of symptoms. According to the researchers, the levels of all spike protein-specific IgG, IgM, and IgA antibodies in the blood positively correlated with levels observed in matched saliva samples. "Given that the virus can also be measured in saliva by PCR, using saliva as a biofluid for both virus and antibody measurements may have some diagnostic value," they wrote in the study.

Long-lived antibodies detected in saliva, blood of coronavirus patients

Health officials in England have approved a test&nbsp;to find out whether people have been infected with coronavirus in the past.

Public Health England (PHE) said the antibody test, developed by Swiss pharmaceutical company Roche, was a "very positive development".

The blood test looks for antibodies to see if a person has already had the virus and might now have some immunity. However,&nbsp;officials have said such tests are not reliable enough until now.

Experts at the government's Porton Down facility evaluated the Roche test last week, Public Health England said, and found it to be "highly specific".

Health minister Edward Argar said the tests would mainly be used on those in the NHS and social care settings to begin with.&nbsp;

<ul>
</ul>

"This is a very positive development because such a highly specific antibody test is a very reliable marker of past infection, said Professor John Newton, national co-ordinator of the UK Coronavirus Testing Programme.

"This in turn may indicate some immunity to future infection although the extent to which the presence of antibodies indicates immunity remains unclear," he said.

Health officials in England have approved a test to find out whether people have been infected with coronavirus in the past. Public Health England (PHE) said the antibody test, developed by Swiss pharmaceutical company Roche, was a "very positive development".

Health officials in England have approved a test to find out whether people have been infected with coronavirus in the past. Public Health England (PHE) said the antibody test, developed by Swiss pharmaceutical company Roche, was a "very positive development". The blood test looks for antibodies to see if a person has already had the virus and might now have some immunity. However, officials have said such tests are not reliable enough until now. Experts at the government's Porton Down facility evaluated the Roche test last week, Public Health England said, and found it to be "highly specific". Health minister Edward Argar said the tests would mainly be used on those in the NHS and social care settings to begin with. "This is a very positive development because such a highly specific antibody test is a very reliable marker of past infection, said Professor John Newton, national co-ordinator of the UK Coronavirus Testing Programme. "This in turn may indicate some immunity to future infection although the extent to which the presence of antibodies indicates immunity remains unclear," he said.

UK approves 'highly accurate' COVID-19 antibody test

At the time when scientists all over the world are searching for possible treatment to combat the COVID-19 outbreak,&nbsp;a study has claimed that antibodies found in llamas could be useful.&nbsp;

Researchers at Ghent University in Belgium are working on antibodies taken from a llama.

These&nbsp;antibodies&nbsp;are&nbsp;a type of protein produced by animal immune systems that fight foreign invaders, which binds tightly to a key protein found on the coronavirus.

According to Dorien de Vlieger, doctoral researcher working on llama antibodies&nbsp;at the university, "llamas have a special type of antibodies. They are&nbsp;smaller in comaparison&nbsp;to human antibodies&nbsp;because they lack certain things. But&nbsp;the advantage of these molecules is that they are very stable. "

A four-year-old&nbsp;female illama named Winter has been&nbsp;injected by a protein present on the surface of the coronavirus, in the hope of developing antivirals that could help in the treatment.

These are the ''first antibodies known to neutralise Sars-CoV-2,'' according&nbsp;to the press release of the study.&nbsp;

''The antibodies could also be used to treat somebody who is already sick to lessen the severity of the disease,''&nbsp;it added.&nbsp;

The researchers have been working on coronaviruses and in 2016 injected on a four-year-old Winter, a llama with SARS and MERS. The antibodies produced helped in targetting SARS virus's spike proteins, which allows it to stick with human cells.&nbsp;

They did a similar experiment, again on Winter,&nbsp;with COVID-19 this year to see the result. The antibodies did bind itself, but it did so "weekly". So, the team linked two copies of the antibody together for an effective result.&nbsp;

However, the team is preparing for more trials with hamsters or primates to further test the study, before applying it to humans. The first set of human testing of antibodies to start by end of the year.

This is not the first time an antibody has been developed from this animal.

There has been a pre-exisiting drug in the market to treat a blood disorder called Thrombotic Thrombo-Ctyopenic Purpura.

However, the antibodies from the camel-like beast are going to be used for the treatment of a respiratory illness fo the very first time. 
&nbsp;

At the time when scientists all over the world are searching for possible treatment to combat the COVID-19 outbreak, a study has claimed that antibodies found in llamas could be useful.

At the time when scientists all over the world are searching for possible treatment to combat the COVID-19 outbreak, a study has claimed that antibodies found in llamas could be useful. Researchers at Ghent University in Belgium are working on antibodies taken from a llama. These antibodies are a type of protein produced by animal immune systems that fight foreign invaders, which binds tightly to a key protein found on the coronavirus. According to Dorien de Vlieger, doctoral researcher working on llama antibodies at the university, "llamas have a special type of antibodies. They are smaller in comaparison to human antibodies because they lack certain things. But the advantage of these molecules is that they are very stable. " A four-year-old female illama named Winter has been injected by a protein present on the surface of the coronavirus, in the hope of developing antivirals that could help in the treatment. These are the ''first antibodies known to neutralise Sars-CoV-2,'' according to the press release of the study. ''The antibodies could also be used to treat somebody who is already sick to lessen the severity of the disease,'' it added. The researchers have been working on coronaviruses and in 2016 injected on a four-year-old Winter, a llama with SARS and MERS. The antibodies produced helped in targetting SARS virus's spike proteins, which allows it to stick with human cells. They did a similar experiment, again on Winter, with COVID-19 this year to see the result. The antibodies did bind itself, but it did so "weekly". So, the team linked two copies of the antibody together for an effective result. However, the team is preparing for more trials with hamsters or primates to further test the study, before applying it to humans. The first set of human testing of antibodies to start by end of the year. This is not the first time an antibody has been developed from this animal. There has been a pre-exisiting drug in the market to treat a blood disorder called Thrombotic Thrombo-Ctyopenic Purpura. However, the antibodies from the camel-like beast are going to be used for the treatment of a respiratory illness fo the very first time.

Llama antibodies can help in treating coronavirus: Study

Scientists in the US and UK have identified a particular&nbsp;mutation called&nbsp;D614G&nbsp;which can make COVID-19 more ''infectious.''

According to a preliminary study conducted by these researchers, this particular mutation&nbsp;is becoming dominant.

Also read:&nbsp;<a href="https://www.wionews.com/world/studies-show-coronavirus-adapts-to-people-china-vaccine-works-in-monkeys-297112" hreflang="en">Studies show coronavirus adapts to people, China vaccine works in monkeys</a>

They&nbsp;have been tracking changes to the "spike" of the virus that gives it its distinctive shape (structure), using a database called the Global Initiative on Sharing All Influenza Data (GISAID).

Monitoring small changes to the structure of the virus is important in understanding the development of vaccines.

Also read:&nbsp;<a href="https://www.wionews.com/world/how-antibody-drugs-are-different-from-vaccines-297054" hreflang="en">How antibody drugs are different from vaccines</a>

Many of the COVID-19 vaccines currently in development target the distinctive spikes of the virus, the idea is that getting human bodies&nbsp;to recognise a unique element of the spike will help it to fight off the whole virus.

But if that spike is changing, a vaccine developed this way could become less effective.

Scientists&nbsp;noted there seems to be something about this particular mutation that makes it grow more quickly.

However, the consequences of this are not yet clear.

The research team analysed UK data from coronavirus patients in Sheffield.

Although they found people with that particular mutation of the virus seemed to have a larger amount of the virus in their samples, they didn't find evidence that those people became sicker or stayed in hospital for longer.

They have not yet established what this will mean for virus spread in the population and for how effective a vaccine might be.

Scientists from all across the globe are identifying mutations of the coronavirus.

&nbsp;

Scientists in the US and UK have identified a particular mutation called D614G which can make COVID-19 more ''infectious.'' According to a preliminary study conducted by these researchers, this particular mutation is becoming dominant.

Scientists in the US and UK have identified a particular mutation called D614G which can make COVID-19 more ''infectious.'' According to a preliminary study conducted by these researchers, this particular mutation is becoming dominant. Also read: Studies show coronavirus adapts to people, China vaccine works in monkeys They have been tracking changes to the "spike" of the virus that gives it its distinctive shape (structure), using a database called the Global Initiative on Sharing All Influenza Data (GISAID). Monitoring small changes to the structure of the virus is important in understanding the development of vaccines. Also read: How antibody drugs are different from vaccines Many of the COVID-19 vaccines currently in development target the distinctive spikes of the virus, the idea is that getting human bodies to recognise a unique element of the spike will help it to fight off the whole virus. But if that spike is changing, a vaccine developed this way could become less effective. Scientists noted there seems to be something about this particular mutation that makes it grow more quickly. However, the consequences of this are not yet clear. The research team analysed UK data from coronavirus patients in Sheffield. Although they found people with that particular mutation of the virus seemed to have a larger amount of the virus in their samples, they didn't find evidence that those people became sicker or stayed in hospital for longer. They have not yet established what this will mean for virus spread in the population and for how effective a vaccine might be. Scientists from all across the globe are identifying mutations of the coronavirus.

Scientists discover coronavirus mutation that can make it more 'infectious'

Israel has made ''significant breakthrough'' in developing an antibody&nbsp;against the deadly coronavirus, according to the country's&nbsp;Defence Minister Naftali Bennett.

The antibody&nbsp;has&nbsp;been developed by the scientists of&nbsp;the country’s main biological research institute,&nbsp;Institute for Biological Research (IIBR).

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
In the past two days, the Israel Institute for Biological Research (IIBR), has completed a groundbreaking scientific development, determining an antibody that neutralizes the corona virus (SARS-COV-2) 1/3
— Ministry of Defense (@Israel_MOD) <a href="https://twitter.com/Israel_MOD/status/1257702056225316870?ref_src=twsrc%5Etfw">May 5, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Also read:&nbsp;<a href="https://www.wionews.com/world/apple-and-google-decide-to-ban-location-tracking-in-their-contact-tracing-apps-296868" hreflang="en">Apple and Google decide to ban location tracking in their contact tracing apps</a>

The researchers have wrapped up the development phase and moved to patent and mass produce the potential treatment.

Bennett visited the labs of the institute&nbsp;supervised by the Prime Minister’s Office and mandated to develop a vaccine for coronavirus in Ness Ziona.

Also read:&nbsp;<a href="https://www.wionews.com/world/now-your-smartphone-can-warn-you-if-youve-been-exposed-to-the-coronavirus-296775" hreflang="en">Now your smartphone can warn you if you’ve been exposed to the coronavirus</a>

He was shown the ''antibody that attacks the virus in a monoclonal way and can neutralize it within the bodies of those ill'', a statement from his office said.

The statement said that the antibody’s development had been completed and that the institute was in the process of patenting the find ''and in the next stage, researchers will approach international companies to produce the antibody on a commercial scale.''

''I am proud of the institute staff for this terrific breakthrough,''&nbsp;Bennett said, adding that ''their creativity and the Jewish mind brought about this amazing achievement.''

Israel has made ''significant breakthrough'' in developing an antibody against the deadly coronavirus, according to the country's Defence Minister Naftali Bennett.

Israel has made ''significant breakthrough'' in developing an antibody against the deadly coronavirus, according to the country's Defence Minister Naftali Bennett. The antibody has been developed by the scientists of the country’s main biological research institute, Institute for Biological Research (IIBR). In the past two days, the Israel Institute for Biological Research (IIBR), has completed a groundbreaking scientific development, determining an antibody that neutralizes the corona virus (SARS-COV-2) 1/3 — Ministry of Defense (@Israel_MOD) May 5, 2020 × Also read: Apple and Google decide to ban location tracking in their contact tracing apps The researchers have wrapped up the development phase and moved to patent and mass produce the potential treatment. Bennett visited the labs of the institute supervised by the Prime Minister’s Office and mandated to develop a vaccine for coronavirus in Ness Ziona. Also read: Now your smartphone can warn you if you’ve been exposed to the coronavirus He was shown the ''antibody that attacks the virus in a monoclonal way and can neutralize it within the bodies of those ill'', a statement from his office said. The statement said that the antibody’s development had been completed and that the institute was in the process of patenting the find ''and in the next stage, researchers will approach international companies to produce the antibody on a commercial scale.'' ''I am proud of the institute staff for this terrific breakthrough,'' Bennett said, adding that ''their creativity and the Jewish mind brought about this amazing achievement.''

Israel makes 'significant breakthrough' in developing antibodies for COVID-19

coronavirus-antibodies

Coronavirus Antibodies, News on Coronavirus Antibodies, stories on Coronavirus Antibodies, articles on Coronavirus Antibodies, Coronavirus Antibodies stories at Wion, Coronavirus Antibodies news, Coronavirus Antibodies latest news